Life Science Division

The Life Science Division was established in 2016 with the aim of broadening our business in high value-added fields. The business is focusing on two main business lines—developing health food ingredients and providing contract manufacturing of antibody drugs.
We are focusing efforts on pyrroloquinoline (PQQ), a vitamin-like substance as key health food ingredient. It has been approved as a health food ingredient in the U.S. and has been selling well as a supplement. It also received approval from the European Commission as a “novel food” under the region’s new food safety regulations. In the contract manufacturing business for antibody drugs, we established Cultivecs in 2016, a joint venture with Nippon Kayaku, which has a proven track record in anticancer drugs and follow-on biologics, and launched the antibody drug contract manufacturing business.